Revenue
2022
2023
2024
2025
BioXcel Therapeutics, Inc. (BTAI)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $642,000 | $2.3M | $1.4M | $375,000 | — | — | — | — | — |
| Research & development | $30.3M | $30.4M | $84.3M | $91.2M | $52.7M | $58.0M | $25.8M | $14.6M | $2.7M |
| Operating expenses | — | — | — | — | $106.9M | $82.3M | $33.6M | $20.0M | $4.5M |
| Operating income | −$50.5M | −$67.2M | −$171.8M | −$159.6M | −$106.9M | −$82.3M | −$33.6M | −$20.0M | −$4.5M |
| EBITDAderived | — | — | — | — | −$106.6M | −$82.1M | −$33.4M | −$19.9M | −$4.5M |
| Net income | −$69.9M | −$59.6M | −$179.1M | −$165.8M | −$106.9M | −$82.2M | −$33.0M | −$19.3M | −$4.5M |
| Basic EPSper diluted share | -$5.73 | -$23.51 | -$98.33 | -$5.92 | -$4.05 | -$3.79 | -$2.02 | -$1.32 | -$0.47 |
| Diluted EPSper diluted share | -$5.73 | -$23.51 | -$98.33 | -$5.92 | -$4.05 | -$3.79 | -$2.02 | -$1.32 | -$0.47 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 20, 2026Form 4 · 10b5-1 | Yocca FrankChief Scientific Officer | SellCommon Stock | 6.8K | $1.09 | $7.5K | 26.2K |
| May 20, 2026Form 4 · 10b5-1 | Rodriguez JavierSee Remarks | SellCommon Stock | 6.6K | $1.08 | $7.1K | 26.8K |
| May 20, 2026Form 4 · 10b5-1 | Steinhart Richard IChief Financial Officer | SellCommon Stock | 6.8K | $1.09 | $7.5K | 26.3K |
| May 20, 2026Form 4 · 10b5-1 | Mehta VimalCEO and President | SellCommon Stock | 19.4K | $1.09 | $21.2K | 69.6K |
| Dec 16, 2024Form 4 · 10b5-1 | O'Neill VincentSee Remarks | SellCommon Stock | 165 | $0.35 | $57.75 | 20.0K |